Survivorship – Bladder / Ureter / Renal Pelvis Cancer

This cancer survivorship algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. This algorithm is provided as informational purposes only and is not intended to replace the independent medical or professional judgment of physicians or other health care providers. Moreover, this algorithm should not be used to treat pregnant women.

ELIGIBILITY

- Bladder cancer 5 or more years after completion of treatment and NED (Patients with suspected or confirmed superficial bladder cancer are excluded from this algorithm)

CONCURRENT COMPONENTS OF VISIT

- Physical exam with each visit
- Years 5-10:
  - BUN, creatinine annually (if patient has continent diversion, obtain vitamin B12 level annually)
  - Urine cytology annually
  - Chest x-ray annually
  - IVP every 2 years (alternate with CT urogram if clinically indicated)
- Years 11-20:
  - BUN, creatinine annually (if patient has continent diversion, obtain vitamin B12 level annually)
  - Urine cytology annually
  - Chest x-ray annually

SURVEILLANCE

- Renal insufficiency
- Ostomy or continence issues
- Sexual health

MONITORING FOR LATE EFFECTS

- Patient education, counseling, and screening:
  - Lifestyle risk assessment
  - Cancer screening
  - HPV vaccination as clinically indicated (see HPV Vaccination Algorithm)
  - Screening for Hepatitis B and C as clinically indicated (see Hepatitis Screening and Management – HBV and HCV Algorithm)
  - Vaccinations as appropriate

RISK REDUCTION/EARLY DETECTION

- Assess for:
  - Distress management (see Distress Screening and Psychosocial Management Algorithm)
  - Body image
  - Financial stressors
  - Social support

PSYCHOSOCIAL FUNCTIONING

DISPOSITION

New primary or recurrent disease?
- Yes
  - Return to primary treating physician
- No
  - Continue survivorship visits

NED = no evidence of disease  IVP = intravenous pyelogram

1 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

2 Includes breast, cervical, colorectal, liver, lung, pancreatic, prostate and skin cancer screening

3 Based on Centers for Disease Control and Prevention (CDC) guidelines

Approved by the Executive Committee of the Medical Staff on 04/24/2018

Department of Clinical Effectiveness V6

Copyright 2018 The University of Texas MD Anderson Cancer Center
Survivorship – Bladder / Ureter / Renal Pelvis Cancer

This cancer survivorship algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. This algorithm is provided as informational purposes only and is not intended to replace the independent medical or professional judgment of physicians or other healthcare providers. Moreover, this algorithm should not be used to treat pregnant women.

SUGGESTED READINGS


European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, treatment, and follow-up of invasive bladder cancer. Annals of Oncology; 16 (supp): i43-i44.


Stephenson AJ. The role of radical cystectomy and bladder-sparing treatments for patients with bladder cancer. Up To Date, June 25, 2009


Department of Clinical Effectiveness V6
Approved by the Executive Committee of the Medical Staff on 04/24/2018
This survivorship algorithm is based majority expert opinion of the Genitourinary Survivorship workgroup at The University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

William Graber, MD (Urology)
Shonice Holdman, MBA*
Deborah A. Kuban, MD (Radiation Oncology Department)
Paula Lewis-Patterson, DNP, RN, NEA-BC (Cancer Survivorship)
William E. Osai, RN, APN, FNP (Genitourinary Medical Oncology)
Jennifer Tinkler, BSN, RN, OCN*

* Clinical Effectiveness Development Team